Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$18.76
+15.0%
$18.73
$13.52
$35.25
$1.65B2.142.31 million shs8.60 million shs
Guardant Health, Inc. stock logo
GH
Guardant Health
$65.06
-2.2%
$52.71
$20.14
$68.00
$8.29B1.462.66 million shs1.91 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$26.00
-0.9%
$32.17
$24.28
$55.33
$1.58B2.311.71 million shs1.28 million shs
Veracyte, Inc. stock logo
VCYT
Veracyte
$30.62
+1.7%
$27.10
$22.61
$47.32
$2.39B2.071.25 million shs1.23 million shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
+15.02%+11.27%-1.88%+10.35%-23.11%
Guardant Health, Inc. stock logo
GH
Guardant Health
-2.18%+2.46%+47.23%+34.39%+164.79%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-0.91%-4.38%-13.94%-14.28%-36.52%
Veracyte, Inc. stock logo
VCYT
Veracyte
+1.69%+7.03%+25.90%+13.49%+1.09%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
2.5202 of 5 stars
3.50.00.00.03.52.50.6
Guardant Health, Inc. stock logo
GH
Guardant Health
3.7242 of 5 stars
1.54.00.04.43.52.50.6
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.8854 of 5 stars
3.41.00.04.43.60.80.6
Veracyte, Inc. stock logo
VCYT
Veracyte
2.9964 of 5 stars
3.40.00.04.32.80.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
3.07
Buy$48.45158.29% Upside
Guardant Health, Inc. stock logo
GH
Guardant Health
3.06
Buy$57.50-11.62% Downside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.73
Moderate Buy$49.4090.00% Upside
Veracyte, Inc. stock logo
VCYT
Veracyte
2.70
Moderate Buy$40.9033.57% Upside

Current Analyst Ratings Breakdown

Latest VCYT, BEAM, GH, and TWST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/8/2025
Veracyte, Inc. stock logo
VCYT
Veracyte
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetUnderweight ➝ Underweight$28.00
8/6/2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$25.00 ➝ $21.00
8/4/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
8/4/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$46.00
7/31/2025
Guardant Health, Inc. stock logo
GH
Guardant Health
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Outperform ➝ Sector Outperform$57.00 ➝ $60.00
7/31/2025
Guardant Health, Inc. stock logo
GH
Guardant Health
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$59.00 ➝ $61.00
7/21/2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/14/2025
Guardant Health, Inc. stock logo
GH
Guardant Health
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/13/2025
Guardant Health, Inc. stock logo
GH
Guardant Health
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$60.00 ➝ $65.00
(Data available from 9/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$60.27M31.49N/AN/A$10.35 per share1.81
Guardant Health, Inc. stock logo
GH
Guardant Health
$828.85M9.79N/AN/A($2.45) per share-26.56
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$362.27M4.33N/AN/A$7.92 per share3.28
Veracyte, Inc. stock logo
VCYT
Veracyte
$445.76M5.40$1.05 per share29.26$15.52 per share1.97
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$376.74M-$4.50N/AN/AN/A-661.31%-43.15%-31.06%11/4/2025 (Estimated)
Guardant Health, Inc. stock logo
GH
Guardant Health
-$436.37M-$3.35N/AN/AN/A-49.93%N/A-28.95%11/5/2025 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$208.73M-$1.45N/AN/AN/A-23.51%-29.03%-21.77%11/17/2025 (Estimated)
Veracyte, Inc. stock logo
VCYT
Veracyte
$24.14M$0.3392.7942.53N/A5.50%6.07%5.53%11/5/2025 (Estimated)

Latest VCYT, BEAM, GH, and TWST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$1.04-$1.00+$0.04-$1.00$13.29 million$8.47 million
8/4/2025Q3 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.54-$0.47+$0.07$0.33$95.52 million$96.06 million
7/30/2025Q2 2025
Guardant Health, Inc. stock logo
GH
Guardant Health
-$0.52-$0.44+$0.08-$0.80$211.19 million$232.09 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$0.904.80%N/AN/A N/A
Guardant Health, Inc. stock logo
GH
Guardant Health
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
Veracyte, Inc. stock logo
VCYT
Veracyte
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
N/A
6.75
6.75
Guardant Health, Inc. stock logo
GH
Guardant Health
N/A
3.71
3.35
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
3.90
3.60
Veracyte, Inc. stock logo
VCYT
Veracyte
N/A
5.43
5.10

Institutional Ownership

CompanyInstitutional Ownership
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
99.68%
Guardant Health, Inc. stock logo
GH
Guardant Health
92.60%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A
Veracyte, Inc. stock logo
VCYT
Veracyte
N/A

Insider Ownership

CompanyInsider Ownership
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
3.50%
Guardant Health, Inc. stock logo
GH
Guardant Health
6.10%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.01%
Veracyte, Inc. stock logo
VCYT
Veracyte
1.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
510101.16 million97.62 millionOptionable
Guardant Health, Inc. stock logo
GH
Guardant Health
2,021124.71 million117.10 millionNot Optionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99060.36 million58.54 millionOptionable
Veracyte, Inc. stock logo
VCYT
Veracyte
79078.67 million77.57 millionOptionable

Recent News About These Companies

Magnetar Financial LLC Invests $651,000 in Veracyte, Inc. $VCYT
Hsbc Holdings PLC Buys 10,618 Shares of Veracyte, Inc. $VCYT
Northern Trust Corp Trims Stake in Veracyte, Inc. $VCYT
Invesco Ltd. Lowers Position in Veracyte, Inc. $VCYT
Veracyte: Q2 Earnings Brings My Position Out Of Mothballs

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Beam Therapeutics stock logo

Beam Therapeutics NASDAQ:BEAM

$18.76 +2.45 (+15.02%)
Closing price 09/3/2025 04:00 PM Eastern
Extended Trading
$18.82 +0.06 (+0.35%)
As of 09/3/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Guardant Health stock logo

Guardant Health NASDAQ:GH

$65.06 -1.45 (-2.18%)
Closing price 09/3/2025 04:00 PM Eastern
Extended Trading
$65.64 +0.58 (+0.89%)
As of 09/3/2025 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$26.00 -0.24 (-0.91%)
Closing price 09/3/2025 04:00 PM Eastern
Extended Trading
$26.10 +0.10 (+0.38%)
As of 09/3/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Veracyte stock logo

Veracyte NASDAQ:VCYT

$30.62 +0.51 (+1.69%)
Closing price 09/3/2025 04:00 PM Eastern
Extended Trading
$30.62 +0.00 (+0.02%)
As of 09/3/2025 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.